Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
18 juin 2020 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
MicroCures Announces Issuance of New European Patent Providing Broad Protection for First-of-its-Kind Cell Movement Decelerator Technology
20 mai 2020 13h01 HE
|
MicroCures, Inc.
Latest Patent Further Strengthens Intellectual Property Portfolio Covering Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Has Key Potential...
MicroCures Announces Issuance of New Patent Covering First-of-its-Kind Cell Movement Decelerator Technology with Potential Applications in Oncology and Fibrosis
14 janv. 2020 08h05 HE
|
MicroCures, Inc.
New Japanese Patent Further Strengthens Intellectual Property Portfolio Covering Company’s Novel Platform for Precisely Controlling Core Cell Migration Mechanisms Decelerator Technology Serves as...
FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
23 oct. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Oct. 23, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with...
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
22 juil. 2019 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with...
University of Virginia Leads Fibrosis Initiative as Part of a Global Effort to Detect and Treat One of the World’s Most Fatal Conditions
20 juin 2019 15h03 HE
|
University of Virginia School of Engineering
Charlottesville, Va., June 20, 2019 (GLOBE NEWSWIRE) -- Fibrosis is often associated with many of the fatal diseases that pervade our globe, riddling organs with stiff tissue that diminishes their...
Helmsley Charitable Trust Grants $4.3 Million to Develop Tools for the Clinical Testing of Anti-fibrotic Treatments for Crohn’s Disease Patients
15 avr. 2019 12h32 HE
|
The Leona M. and Harry B. Helmsley Charitable Trust
New York, NY, April 15, 2019 (GLOBE NEWSWIRE) -- The Leona M. and Harry B. Helmsley Charitable Trust has awarded $4.3 million to Cleveland Clinic, Mayo Clinic, and Robarts Clinical Trials, Inc. to...
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
08 janv. 2018 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V....
Galectin Therapeutics CEO Peter G. Traber, M.D. Named Chair of the Anti-Fibrotic Drug Development Summit 2017
13 nov. 2017 09h00 HE
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced that Peter G. Traber, M.D.,...